FSLR
49
-3
HPE
53
2
CRM
62
3
NEE
54
-3
KEY
43
-3
COP
44
-3
MNST
61
-4
KO
38
2
AEE
51
-7
L
55
-4
SRCL
39
5
OMC
58
-4
OI
38
-4
CMI
50
-4
CPB
30
-5
XRAY
20
-2
JWN
60
3
CVS
41
-2
SWK
46
-10
ACN
56
2
FSLR
49
-3
HPE
53
2
CRM
62
3
NEE
54
-3
KEY
43
-3
COP
44
-3
MNST
61
-4
KO
38
2
AEE
51
-7
L
55
-4
SRCL
39
5
OMC
58
-4
OI
38
-4
CMI
50
-4
CPB
30
-5
XRAY
20
-2
JWN
60
3
CVS
41
-2
SWK
46
-10
ACN
56
2
Financhill
Back

Keros Therapeutics 10K Form

Buy
60

KROS
Keros Therapeutics

Last Price:
60.76
Seasonality Move:
38.45%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive KROS News And Ratings

See the #1 stock for the next 7 days that we like better than KROS

KROS Financial Statistics

Sales & Book Value

Annual Sales: $151K
Cash Flow: $-40.11M
Price / Cash Flow: 0
Annual Sales: $11.64
Price / Book: 5.36

Profitability

EPS (TTM): -5.13000
Net Income (TTM): $-168.05M
Gross Margin: --
Return on Equity: -45.94%
Return on Assets: -42.15%

Keros Therapeutics Earnings Forecast

Key Keros Therapeutics Financial Ratios

  • The Research & Development expenses have been 89,574.83% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of KROS is -101,319.21% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 1 years.

Keros Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: KROS
CUSIP: 492327
Website: kerostx.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 20.37
Quick Ratio: 19.17

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

KROS Technical Analysis vs Fundamental Analysis

Buy
60
Keros Therapeutics (KROS) is a Buy

Is Keros Therapeutics a Buy or a Sell?